Asian stock markets a sea on Friday, following the broad sell-off on Wall Street overnight, amid a renewed sell-off in the tech sector, with the tech-heavy NASDAQ plummeting on concerns about the sustainability of the AI trade amid expected tighter AI regulation after Democrats' takeover of both houses of Congress. Concerns of global inflation returns as crude oil prices spike again. Asian markets ended mixed on Thursday.
The selloff intensified after a sweeping Democratic victory in the US midterm elections raised concerns over tighter AI industry regulations and a possible slowdown in data center expansion.
For comments and feedback contact: [email protected]
Market Analysis
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.